However, NF-κB inhibition alone cannot account for the overall anti-MM activity of bortezomib, as demonstrated by studies comparing bortezomib to the IKK-B-specific inhibitor PS1145 (3). Here, NFKB1 is linked to Miyoshi myopathy.